ALLO

ALLO

• CEO:
• Employees:
• Sector:
• Industry:

ALLO News

Latest news about the ALLO

• 
  Allogene Therapeutics Inc (ALLO) Q3 2021 Earnings Call Transcript

  ALLO earnings call for the period ending September 30, 2021.

  by The Motley Fool at 11/5/21, 12:00 AMView More →
• 
  Analysis-Deals, data buzz could help biotech shares exit Wall St's 'no man's land'

  Sluggish U.S. biotech shares could require a wave of deal-making or exciting clinical trial results if the sector wants to join the stock market's party after lagging Wall Street's broad advance this year.

  by Reuters at 10/15/21, 8:45 AMView More →
• 
  Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week

  A key gene-editing readout had Cathie Wood shuffling her portfolio.

  by The Motley Fool at 10/15/21, 12:00 AMView More →
• 
  Why Allogene Therapeutics Stock Is Getting Hammered Today

  A possible safety issue is crushing the biotech's shares today.

  by The Motley Fool at 10/8/21, 12:00 AMView More →
• 
  4 Companies That Could Upend the Pharma Industry

  Their groundbreaking research on CAR T-cell therapies could revolutionize how certain cancers are treated in the future.

  by The Motley Fool at 7/29/20, 12:00 AMView More →
• 
  BRIEF-Allogene Therapeutics Announces Pricing Of Public Offering Of Common Stock

  * ALLOGENE THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

  by Reuters at 6/2/20, 1:14 AMView More →
• 
  BRIEF-Allogene Therapeutics Commences Public Offering Of Common Stock

  * ALLOGENE THERAPEUTICS ANNOUNCES COMMENCEMENT OF PUBLIC OFFERING OF COMMON STOCK

  by Reuters at 6/1/20, 10:32 AMView More →
• 
  BRIEF-Allogene Therapeutics, With Collaborator Servier, Reports Positive Results From Its Phase 1 Alpha Study Of Allo-501 In Relapsed/Refractory Non-Hodgkin Lymphoma

  * ALLOGENE THERAPEUTICS, WITH COLLABORATOR SERVIER, REPORTS POSITIVE RESULTS FROM ITS PHASE 1 ALPHA STUDY OF ALLO-501 IN RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING

  by Reuters at 5/29/20, 12:31 PMView More →
• 
  U.S. RESEARCH ROUNDUP-CVS Health, Regal Beloit, Zuora

  Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including CVS Health, Regal Beloit and Zuora, on Thursday. HIGHLIGHT * CVS Health Corp : Credit Suisse raises to outperform from neutral * Dow Inc : HSBC cuts to hold...

  by Reuters at 5/14/20, 2:54 PMView More →
• 
  Here's Why Allogene Therapeutics Is Roaring Higher Today

  The development-stage biopharma reported encouraging, albeit early, data from an important pipeline program.

  by The Motley Fool at 5/14/20, 12:00 AMView More →